Raddatz, Dirk

[["dc.bibliographiccitation.firstpage","209"],["dc.bibliographiccitation.issue","3"],["dc.bibliographiccitation.journal","OSTEOLOGIE"],["dc.bibliographiccitation.lastpage","216"],["dc.bibliographiccitation.volume","18"],["dc.contributor.author","Siggelkow, Heide"],["dc.contributor.author","Cortis, Judith"],["dc.contributor.author","Claus, Ch."],["dc.contributor.author","Funke, M."],["dc.contributor.author","Nolte, W."],["dc.contributor.author","Huefner, Michael"],["dc.contributor.author","Raddatz, Dirk"],["dc.date.accessioned","2018-11-07T08:35:18Z"],["dc.date.available","2018-11-07T08:35:18Z"],["dc.date.issued","2009"],["dc.description.abstract","Crohn's disease (CD) is associated with reduced bone mineral density and increased fracture risk. To assess the effects of the inflammatory process itself on bone parameters, we investigated patients with active CD and in remission without glucocorticoid treatment four weeks prior to analysis. Patients with active CD were compared to age- and sex-matched healthy volunteers and osteoporosis patients. Bone mineral density, bone formation and resorption markers were assessed, in addition to simple inflammatory markers and cytokines. Out of seven patients with active disease, three had osteopenia and one osteoporosis (WHO definition). The erythrocyte sedimentation rate (ESR) was associated with BMD at the femoral neck (R(2) = 0.853, p<0.01) and the spine (R(2)=0.772, p<0.05). ESR seems to influence bone formation, as shown by lower bone alkaline phosphatase with high ESR (R(2)=0.725, R=-0.852, p<0.05). The clinical disease activity score was not useful in determining patients' risk of acquiring bone disease. in conclusion, in patients with Crohn's disease, the degree of the inflammatory process as assessed by ESR indicates bone loss and might be of value in identifying patients at risk of developing osteoporosis."],["dc.identifier.isi","000271412000009"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/18032"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Verlag Hans Huber"],["dc.relation.issn","1019-1291"],["dc.title","Erythrocyte sedimentation rate as an osteoporosis risk factor in patients with active Crohn's disease"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","389"],["dc.bibliographiccitation.issue","4"],["dc.bibliographiccitation.journal","European Journal of Gastroenterology & Hepatology"],["dc.bibliographiccitation.lastpage","395"],["dc.bibliographiccitation.volume","16"],["dc.contributor.author","Wietzke-Braun, Perdita"],["dc.contributor.author","Schindler, C."],["dc.contributor.author","Raddatz, Dirk"],["dc.contributor.author","Braun, F."],["dc.contributor.author","Armbrust, T."],["dc.contributor.author","Nolte, W."],["dc.contributor.author","Ramadori, Giuliano"],["dc.date.accessioned","2018-11-07T10:49:51Z"],["dc.date.available","2018-11-07T10:49:51Z"],["dc.date.issued","2004"],["dc.description.abstract","Objective Patients with non-resectable liver metastases of colorectal cancer have poor prognosis and are mainly treated by palliative chemotherapy. Laser interstitial thereto-therapy is an innovative minimal invasive procedure for local tumour destruction within solid organs. The aim of the study was to investigate quality of life and outcome of ultrasound-guided laser interstitial thermotherapy (US-LITT) in patients with liver metastases of colorectal cancer. Methods In this prospective non-randomized study, 45 patients with liver metastases of colorectal cancer were palliatively treated by US-LITT. Patient survival was analysed by the Kaplan-Meier method and the quality of life by questionnaire C30 of the European Organisation for Research and Treatment of Cancer before, and 1 week, 1 month, and 6 months after initiation of US-LITT. Results Median survival after initiation of US-LITT was 8.5 +/- 0.7 months with a range of 1.5-18 months. Body weight was constant 1 month after US-LITT. In the multivariate analyses, quality-of-life symptoms and functioning scales did not deteriorate in patients alive at 6 months after initiation of US-LITT. Univariate analyses outlined a significant increase of the pain subscale before and at 1 week after US-LITT. Conclusions This study first describes the quality of life in patients with liver metastases of colorectal cancer treated by US-LITT. Potential benefits of the minimal invasive procedure could be prolonged survival time by preserved quality of life, but this first impression needs to be verified in a comparative study."],["dc.identifier.doi","10.1097/00042737-200404000-00004"],["dc.identifier.isi","000220655900004"],["dc.identifier.pmid","15028971"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/48527"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Lippincott Williams & Wilkins"],["dc.relation.issn","0954-691X"],["dc.title","Quality of life and outcome of ultrasound-guided laser interstitial thereto-therapy for non-resectable liver metastases of colorectal cancer"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","461"],["dc.bibliographiccitation.issue","8"],["dc.bibliographiccitation.journal","Experimental and Clinical Endocrinology & Diabetes"],["dc.bibliographiccitation.lastpage","467"],["dc.bibliographiccitation.volume","116"],["dc.contributor.author","Raddatz, Dirk"],["dc.contributor.author","Nolte, W."],["dc.contributor.author","Rossbach, C."],["dc.contributor.author","Leonhardt, U."],["dc.contributor.author","Buchwald, A."],["dc.contributor.author","Scholz, Karl Heinrich"],["dc.contributor.author","Ramadori, Giuliano"],["dc.date.accessioned","2018-11-07T11:12:26Z"],["dc.date.available","2018-11-07T11:12:26Z"],["dc.date.issued","2008"],["dc.description.abstract","Background: Diabetes in liver cirrhosis is associated with a blunted insulin response, which might be explained by an impaired release of the incretin hormone glucagon-like peptide 1 (GLP-1) into the portal circulation. Aims: To investigate basal and stimulated portal venous and peripheral GLP-1 concentrations in non-diabetic (ND) and diabetic (D) patients with liver cirrhosis undergoing transjugular intrahepatic portosystemic stent shunt (TIPSS) implantation. Patients and Methods: After elective TIPSS portalvenous and peripheral probes were drawn from 10 ND and 10 D patients with stable liver disease during an oral metabolic test and plasma glucose, immunoreactive GLP-1, insulin and C-peptide were measured. Results: The study meal led to a significant rise in portal GLP-1 levels in ND and D. Basal and stimulated portal GLP-1 concentrations were not significantly different between ND and D. Peripheral GLP-1 did not differ significantly from portal venous levels. Insulin response in ND was more pronounced in the portal blood than in the periphery and was absent in D. Conclusion: TIPSS allows a direct evaluation of hormonal changes in the portal circulation during an oral metabolic tolerance test. A disturbed GLP-1 secretion does not play a role in blunting the insulin response observed in patients with hepatogenous diabetes."],["dc.identifier.doi","10.1055/s-2007-1004596"],["dc.identifier.isi","000259927300002"],["dc.identifier.pmid","18770489"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/53665"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Johann Ambrosius Barth Verlag Medizinverlage Heidelberg Gmbh"],["dc.relation.issn","0947-7349"],["dc.title","Measuring the effect of a study meal on portal concentrations of glucagon-like peptide 1 (GLP-1) in non diabetic and diabetic patients with liver cirrhosis: Transjugular intrahepatic portosystemic stent shunt (TIPSS) as a new method for metabolic measurements"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","268"],["dc.bibliographiccitation.issue","5"],["dc.bibliographiccitation.journal","Experimental and Clinical Endocrinology & Diabetes"],["dc.bibliographiccitation.lastpage","274"],["dc.bibliographiccitation.volume","113"],["dc.contributor.author","Raddatz, Dirk"],["dc.contributor.author","Rossbach, C."],["dc.contributor.author","Buchwald, A."],["dc.contributor.author","Scholz, Karl Heinrich"],["dc.contributor.author","Ramadori, Giuliano"],["dc.contributor.author","Nolte, W."],["dc.date.accessioned","2018-11-07T11:03:20Z"],["dc.date.available","2018-11-07T11:03:20Z"],["dc.date.issued","2005"],["dc.description.abstract","Background: Hyperglucagonemia has been described to be associated with insulin resistance in patients with liver cirrhosis. Portosystemic shunts may be involved in the etiology of hyperglucagonemia. To test this hypothesis we investigated fasting peripheral plasma glucagon levels before and after portal decompression by transjugular intrahepatic portosystemic shunting (TIPS). Methods: Glucagon, insulin, plasma glucose, HbA1c, and C-peptide were determined in peripheral venous samples from 21 non-diabetic (ND)- and 15 diabetic patients (1); 3 treated with insulin, 3 with sulfonylurea, 9 with diet alone) with liver cirrhosis, showing comparable clinical features (gender, age, BMI, creatinine, Child-Pugh-score, complications, and etiology of liver cirrhosis) before, 3 and 9 months after elective TIPS implantation. insulin resistance was calculated as R-HOMA according to the homeostasis model assessment (HOMA). Results: Glucagon levels before TIPS were elevated in patients with diabetes compared to patients without diabetes (1): 145.4 &PLUSMN; 52.1 pg/ml vs. ND: 97.3 &PLUSMN; 49.8 pg/ml; p = 0.057). 3 and 9 months after TIPS implantation glucagon levels increased significantly in ND (188.9 &PLUSMN; 80.3 pg/ml and 187.2 &PLUSMN; 87.6 pg/ml) but not in D (169.6 &PLUSMN; 62.4 pg/ml and 171.9 &PLUSMN; 58.4 pg/ml). While plasma glucose, HbA1c, and C-peptide were significantly higher in D than in ND, they did not change significantly 3 and 9 months after TIPS implantation. Insulin was increased in D before TIPS (1): 31.6 &PLUSMN; 15.9 mU/l vs. ND: 14.8 &PLUSMN; 7.1 mU/l; p = 0.0001). 3 and 9 months after TIPS insulin significantly increased in ND (26.6 &PLUSMN; 14.7 mU/l and 23.2 &PLUSMN; 10.9 mU/l vs. 14.8 &PLUSMN; 7.1 mU/l before TIPS) but not in D. In ND R-HOMA also increased from 3.5 &PLUSMN; 2 mU x mmol/l(2) to 5.7 &PLUSMN; 3.3 mU x mmol/l(2) after 3 and 5.4 &PLUSMN; 2.6 mU x mmol/l(2) after 9 months. BMI, liver and kidney function did not change with time. Conclusion: In nondiabetic cirrhotic patients TIPS implantation is followed by an increase of glucagon. However, this does not result in a worsening of glycemic control, probably because of a simultaneous increase of insulin."],["dc.identifier.doi","10.1055/s-2005-837546"],["dc.identifier.isi","000229605500006"],["dc.identifier.pmid","15926112"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/51593"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Johann Ambrosius Barth Verlag Medizinverlage Heidelberg Gmbh"],["dc.relation.issn","0947-7349"],["dc.title","Fasting hyperglucagonemia in patients with transjugular intrahepatic portosystemic shunts (TIPS)"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.issue","2"],["dc.bibliographiccitation.journal","Bone"],["dc.bibliographiccitation.volume","44"],["dc.contributor.author","Clasen, T. J."],["dc.contributor.author","Raddatz, Dirk"],["dc.contributor.author","Schnell, R."],["dc.contributor.author","Nolte, W."],["dc.contributor.author","Press, A."],["dc.contributor.author","Siggelkow, Heide"],["dc.date.accessioned","2018-11-07T08:28:58Z"],["dc.date.available","2018-11-07T08:28:58Z"],["dc.date.issued","2009"],["dc.format.extent","S419"],["dc.identifier.doi","10.1016/j.bone.2009.03.349"],["dc.identifier.isi","000266348600559"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/16540"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Elsevier Science Inc"],["dc.publisher.place","New york"],["dc.relation.conference","36th European Symposium on Calcified Tissues"],["dc.relation.eventlocation","Vienna, AUSTRIA"],["dc.relation.issn","8756-3282"],["dc.title","Influence of inflammation on bone density in patients with inflammatory bowel disease - Different effects on different structures within bone?"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]